Chapter 35 - The Brussels Conclave

The European capital was cloaked in gray drizzle when our private car pulled up near the grand neoclassical facade of the European Council building in Brussels. Behind closed mahogany doors in an opulent private hotel nearby, thirty chief executive officers from the world's most lucrative pharmaceutical conglomerates had gathered under the banner of the European Life Sciences Alliance.
They had invited senior European regulatory commissioners to a private banquet under the pretext of discussing pandemic preparedness. In reality, draft legislation had already been prepared by their lobbyists: Article 44-B, a clause that would allow member states to forcibly expropriate the intellectual property of any medical patent deemed "systemically critical to public infrastructure" and license it back to commercial manufacturers at government-fixed rates.
In short: they wanted to strip Hartwell Biosciences of its patents under the guise of public safety, then hand the manufacturing monopolies back to themselves.
I didn't wait for an invitation.
Dressed in a pristine pearl-white suit with an emerald brooch pinned to my lapel, I walked through the hotel lobby accompanied by Marcus, Annalise, and Dr. Laurent Dubois—the Chief Medical Ethicist for the French National Health Service and a vocal supporter of our open-source movement.
The two security guards outside the private ballroom stepped forward to block the entrance.
"Private event, madam," the lead guard stated stiffly.
Annalise didn't even slow her stride. She flashed an official parliamentary observer credential issued by the European Committee on Health and Bioethics. "Stand aside, young man, before you find yourself named as an obstruction witness in an active parliamentary integrity inquiry."
The guard hesitated, caught between corporate orders and official regulatory badges. I placed my gloved hand on the heavy brass door and pushed it open.
The cavernous ballroom went instantly silent. Thirty corporate executives froze, crystal wine glasses halfway to their mouths. At the head of the banquet table sat Baron Philippe de Montmorency, the aristocratic chairman of Montmorency Pharma, a man who had spent four decades dominating European oncology pricing.
Montmorency slowly lowered his glass, his aristocratic face hardening with haughty displeasure. "Dr. Hartwell. This is an executive caucus for members of the European Life Sciences Alliance. You have not registered, nor are you a recognized member."
"I don't need a membership card to attend a meeting where my intellectual property is being put up for an illegal auction, Baron," I said, my voice echoing effortlessly across the high-ceilinged room as I walked down the carpeted aisle toward his seat.
May you like
Several executives shifted uncomfortably in their chairs, looking down at their linen napkins. They had spent months meeting in private, convincing themselves that Evelyn Hartwell was just a reclusive American scientist who would accept a polite buyout once European bureaucrats applied legal pressure.
They were about to learn that I had spent my life dismantling far more formidable bullies than a room full of aging corporate aristocrats.